Latest Insider Transactions at Novo Cure LTD (NVCR)
This section provides a real-time view of insider transactions for Novo Cure LTD (NVCR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NovoCure Ltd to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NovoCure Ltd's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
367
+2.56%
|
$12,845
$35.28 P/Share
|
|
Jun 30
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
367
+0.36%
|
$12,845
$35.28 P/Share
|
|
Jun 30
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
288
+0.81%
|
$10,080
$35.28 P/Share
|
|
Jun 30
2023
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
357
+0.53%
|
$12,495
$35.28 P/Share
|
|
Jun 30
2023
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
367
+0.29%
|
$12,845
$35.28 P/Share
|
|
Jun 07
2023
|
Gabriel Leung |
BUY
Grant, award, or other acquisition
|
Direct |
3,853
+4.64%
|
-
|
|
Jun 07
2023
|
Timothy J Scannell |
BUY
Grant, award, or other acquisition
|
Direct |
3,853
+49.52%
|
-
|
|
Jun 07
2023
|
W Anthony Vernon |
BUY
Grant, award, or other acquisition
|
Direct |
3,853
+2.27%
|
-
|
|
Mar 07
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
8,318
-6.84%
|
$623,850
$75.29 P/Share
|
|
Mar 03
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
593
-0.89%
|
$45,068
$76.16 P/Share
|
|
Mar 03
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,505
-2.59%
|
$418,380
$76.16 P/Share
|
|
Mar 03
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
25,635
-3.7%
|
$1,948,260
$76.16 P/Share
|
|
Mar 03
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
21,421
-5.01%
|
$1,627,996
$76.16 P/Share
|
|
Mar 03
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
7,350
-3.61%
|
$558,600
$76.65 P/Share
|
|
Mar 03
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,808
+9.95%
|
-
|
|
Mar 03
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,986
+9.42%
|
-
|
|
Mar 03
2023
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,182
+13.25%
|
-
|
|
Mar 03
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,766
+14.77%
|
-
|
|
Mar 03
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
11,808
+14.44%
|
-
|
|
Mar 02
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,055
-1.1%
|
$79,125
$75.28 P/Share
|
|
Mar 02
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,213
-0.66%
|
$90,975
$75.28 P/Share
|
|
Mar 02
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
937
-0.94%
|
$70,275
$75.28 P/Share
|
|
Mar 02
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
281
-0.42%
|
$21,075
$75.28 P/Share
|
|
Mar 02
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
4,951
-2.66%
|
$371,325
$75.55 P/Share
|
|
Mar 01
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
1,923
-1.89%
|
$146,148
$76.36 P/Share
|
|
Mar 01
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
1,684
-2.6%
|
$127,984
$76.36 P/Share
|
|
Mar 01
2023
|
Ashley Cordova Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,198
-2.24%
|
$167,048
$76.36 P/Share
|
|
Mar 01
2023
|
William Patrick Burke Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
755
-1.11%
|
$57,380
$76.36 P/Share
|
|
Mar 01
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,164
-1.16%
|
$164,464
$76.36 P/Share
|
|
Feb 28
2023
|
Pritesh Shah Chief Growth Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,055
+15.75%
|
-
|
|
Feb 28
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
18,621
+22.33%
|
-
|
|
Feb 28
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,818
+19.51%
|
-
|
|
Feb 28
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
17,755
+33.72%
|
-
|
|
Feb 28
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,992
+18.76%
|
-
|
|
Feb 28
2023
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,125
+15.19%
|
-
|
|
Feb 28
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,653
+10.39%
|
-
|
|
Jan 06
2023
|
Barak Ben Arye General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
150
+0.87%
|
$9,300
$62.3 P/Share
|
|
Jan 06
2023
|
William Patrick Burke Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108
+0.19%
|
$6,696
$62.3 P/Share
|
|
Jan 06
2023
|
Ely Benaim Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98
+0.34%
|
$6,076
$62.3 P/Share
|
|
Jan 06
2023
|
Wilhelmus Cm Groenhuysen Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
102
+0.06%
|
$6,324
$62.3 P/Share
|
|
Jan 06
2023
|
Ashley Cordova Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66
+0.09%
|
$4,092
$62.3 P/Share
|
|
Jan 06
2023
|
Asaf Danziger Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.29%
|
$2,418
$62.3 P/Share
|
|
Jan 05
2023
|
Pritesh Shah Chief Growth Officer |
SELL
Open market or private sale
|
Direct |
387
-0.47%
|
$41,796
$108.0 P/Share
|
|
Jan 05
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
SELL
Open market or private sale
|
Direct |
39,507
-8.32%
|
$4,464,291
$113.0 P/Share
|
|
Jan 05
2023
|
Frank X Leonard EVP, Pres., Novocure Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
35,209
+11.66%
|
$528,135
$15.06 P/Share
|
|
Jan 05
2023
|
Uri Weinberg Chief Innovation Officer |
SELL
Open market or private sale
|
Direct |
8,143
-4.26%
|
$952,731
$117.0 P/Share
|
|
Jan 05
2023
|
Uri Weinberg Chief Innovation Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,946
+3.82%
|
$91,462
$47.04 P/Share
|
|
Jan 05
2023
|
Asaf Danziger Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
212,500
-19.01%
|
$24,437,500
$115.25 P/Share
|
|
Jan 05
2023
|
Asaf Danziger Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
212,500
+43.79%
|
$1,912,500
$9.31 P/Share
|
|
Dec 02
2022
|
Ashley Cordova Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+2.62%
|
$14,000
$7.15 P/Share
|